Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19
Yıl: 2021 Cilt: 51 Sayı: 4 Sayfa Aralığı: 1675 - 1681 Metin Dili: İngilizce DOI: 10.3906/sag-2103-80 İndeks Tarihi: 11-01-2022
Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19
Öz: Background and aim: The aim of this study is to evaluate whether the long-term (≥4 weeks) use of proton pump inhibitors (PPIs) is a risk factor for intubation requirement and mortality in patients hospitalized for COVID-19. Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (≥18 years of age) with confirmed COVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods during which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included those who have used PPIs for more than 4 weeks. Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068), current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were found to be independent risk factors for mortality. Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.Key words: Covid-19, proton pump inhibitors, mortality
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. Journal of Medical Virology 2020; 92 (4): 401-402. doi: 10.1002/jmv.25678
- 2. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-medica: Atenei Parmensis 2020; 91 (1): 157-160. doi: 10.23750/abm.v91i1.9397
- 3. Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine 2020; 382 (8): 727-733. doi: 10.1056/NEJMoa2001017
- 4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 2020; 109: 102433. doi: 10.1016/j. jaut.2020.102433
- 5. Savarino V, Mela GS, Zentilin P, Bisso G, Pivari M et al Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Alimentary Pharmacology & Therapeutics 1998; 12 (12): 1241- 1247. doi: 10.1046/j.1365-2036.1998.00416.x
- 6. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E et al. American Gastroenterological Association Medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135 (4): 1383-1391, 1391 e1-5. doi: 10.1053/j.gastro.2008.08.045
- 7. Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Cinical Pharmacology 2018; 11 (11): 1123- 1134. doi: 10.1080/17512433.2018.1531703
- 8. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. American Heart Journal 2009; 157 (1): 148. doi: 10.1016/j.ahj.2008.09.017
- 9. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Internal Medicine 2016; 176 (2): 172- 174. doi: 10.1001/jamainternmed.2015.7927
- 10. Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes 2017; 8 (4): 351-358. doi: 10.1080/19490976.2017.1284732
- 11. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM et al. Use of acidsuppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ: Canadian Medical Association journal = Journal De l’Association Medicale Canadienne 2011; 183 (3): 310-319. doi: 10.1503/cmaj.092129
- 12. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and metaanalysis. PLoS One 2015; 10 (6): e0128004. doi: 10.1371/ journal.pone.0128004
- 13. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics 2011; 34 (11-12): 1269-1281. doi: 10.1111/j.1365-2036.2011.04874.x
- 14. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153 (1): 35- 48. doi: 10.1053/j.gastro.2017.04.047
- 15. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. The American Journal of Gastroenterology 2020; 115 (10): 1707- 1715. doi: 10.14309/ajg.0000000000000798
- 16. Darnell ME, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. Journal of Virological Methods 2004; 121 (1): 85-91. doi: 10.1016/j.jviromet.2004.06.006
- 17. Chen L, Lou J, Bai Y, Wang M. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. The American Journal of Gastroenterology 2020; 115 (5): 790. doi: 10.14309/ajg.0000000000000610
- 18. Wu Y, Guo C, Tang L, Hong Z, Zhou J et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The Lancet Gastroenterology & Hepatology 2020; 5 (5): 434-435. doi: 10.1016/S2468-1253(20)30083-2
- 19. Lamers MM, Beumer J, Van der Vaart J, Knoops K, Puschhof J et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369 (6499): 50-54. doi: 10.1126/science.abc1669
- 20. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M et al. Role of the normal gut microbiota.World Journal of Gastroenterology 2015; 21 (29): 8787-803. doi: 10.3748/wjg.v21.i29.8787
- 21. Belizario JE, Faintuch J, Garay-Malpartida M. Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. Mediators of Inflammation 2018; 2018: 2037838. doi: 10.1155/2018/2037838
- 22. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33 (5): 617-621. doi: 10.1136/ gut.33.5.617
- 23. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Practice & Research Clinical Gastroenterology 2001; 15 (3): 355-70. doi: 10.1053/ bega.2001.0184
- 24. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F et al. Omeprazole treatment diminishes intraand extracellular neutrophil reactive oxygen production and bactericidal activity. Critical Care Medicine 2002; 30 (5): 1118- 1122. doi: 10.1097/00003246-200205000-00026
- 25. Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021; 70 (1): 76-84. doi: 10.1136/ gutjnl-2020-322248
- 26. Ramachandran P, Perisetti A, Gajendran M, Jean-Louis F, Bansal P et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. European Journal of Gastroenterology & Hepatology 2020. doi: 0.1097/ MEG.0000000000002013
- 27. Wu C, Liu Y, Yang Y, Zhang P, Zhong W et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020; 10 (5): 766-788. doi: 10.1016/j.apsb.2020.02.008
- 28. Hariyanto TI, Prasetya IB, Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Digestive and Liver Disease: Official Journal of The Italian Society of Gastroenterology and The Italian Association for The Study of the Liver 2020; 52 (12): 1410-1412. doi: 10.1016/j.dld.2020.10.001
- 29. Ray A, Sharma S, Sadasivam B. The potential therapeutic role of proton pump inhibitors in COVID-19: hypotheses based on existing evidences. Drug Research (Stuttgart) 2020; 70 (10): 484-488. doi: 10.1055/a-1236-3041
| APA | Yozgat A, Kasapoglu B, Can G, Tanoglu A, Sakin Y, YALÇIN K, Gürler M, Kaplan M, Kaban M, kırsoy m, Kara U, kekilli m (2021). Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. , 1675 - 1681. 10.3906/sag-2103-80 |
| Chicago | Yozgat Ahmet,Kasapoglu Benan,Can Güray,Tanoglu Alpaslan,Sakin Yusuf Serdar,YALÇIN Kadir Serkan,Gürler Müjgan,Kaplan Mustafa,Kaban Mehmet göktürk,kırsoy mehmet,Kara Umut,kekilli murat Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. (2021): 1675 - 1681. 10.3906/sag-2103-80 |
| MLA | Yozgat Ahmet,Kasapoglu Benan,Can Güray,Tanoglu Alpaslan,Sakin Yusuf Serdar,YALÇIN Kadir Serkan,Gürler Müjgan,Kaplan Mustafa,Kaban Mehmet göktürk,kırsoy mehmet,Kara Umut,kekilli murat Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. , 2021, ss.1675 - 1681. 10.3906/sag-2103-80 |
| AMA | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. . 2021; 1675 - 1681. 10.3906/sag-2103-80 |
| Vancouver | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. . 2021; 1675 - 1681. 10.3906/sag-2103-80 |
| IEEE | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m "Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19." , ss.1675 - 1681, 2021. 10.3906/sag-2103-80 |
| ISNAD | Yozgat, Ahmet vd. "Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19". (2021), 1675-1681. https://doi.org/10.3906/sag-2103-80 |
| APA | Yozgat A, Kasapoglu B, Can G, Tanoglu A, Sakin Y, YALÇIN K, Gürler M, Kaplan M, Kaban M, kırsoy m, Kara U, kekilli m (2021). Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences, 51(4), 1675 - 1681. 10.3906/sag-2103-80 |
| Chicago | Yozgat Ahmet,Kasapoglu Benan,Can Güray,Tanoglu Alpaslan,Sakin Yusuf Serdar,YALÇIN Kadir Serkan,Gürler Müjgan,Kaplan Mustafa,Kaban Mehmet göktürk,kırsoy mehmet,Kara Umut,kekilli murat Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences 51, no.4 (2021): 1675 - 1681. 10.3906/sag-2103-80 |
| MLA | Yozgat Ahmet,Kasapoglu Benan,Can Güray,Tanoglu Alpaslan,Sakin Yusuf Serdar,YALÇIN Kadir Serkan,Gürler Müjgan,Kaplan Mustafa,Kaban Mehmet göktürk,kırsoy mehmet,Kara Umut,kekilli murat Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences, vol.51, no.4, 2021, ss.1675 - 1681. 10.3906/sag-2103-80 |
| AMA | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences. 2021; 51(4): 1675 - 1681. 10.3906/sag-2103-80 |
| Vancouver | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences. 2021; 51(4): 1675 - 1681. 10.3906/sag-2103-80 |
| IEEE | Yozgat A,Kasapoglu B,Can G,Tanoglu A,Sakin Y,YALÇIN K,Gürler M,Kaplan M,Kaban M,kırsoy m,Kara U,kekilli m "Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19." Turkish Journal of Medical Sciences, 51, ss.1675 - 1681, 2021. 10.3906/sag-2103-80 |
| ISNAD | Yozgat, Ahmet vd. "Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19". Turkish Journal of Medical Sciences 51/4 (2021), 1675-1681. https://doi.org/10.3906/sag-2103-80 |
